After more than a week of delays, two new NASA missions have gotten the greenlight to head to space tonight (March 8).
With numerous companies investing in novel primary immune deficiency therapies, the pharmaceutical product launch of emerging treatments is expected to reshape the competitive landscape significantly.
The new Neutron rocket includes a "hippo" mouth fairing that deploys upper stages by spitting them out from inside.
Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...
Credit: JHU/APL If all goes to plan, the spacecraft for both missions will separate from Falcon 9 within an hour after launch — SPHEREx will deploy first, about 42 minutes after liftoff ...
With deep expertise in market trends, competitor strategies, and industry developments, DelveInsight helps clients stay ahead by offering detailed analysis on launch timelines, regulatory updates ...